Skip to main content

Table 1 Baseline characteristics of the study population (n = 74)

From: Relationship between polyunsaturated fatty acid composition in serum phospholipids, systemic low-grade inflammation, and glycemic control in patients with type 2 diabetes and atherosclerotic cardiovascular disease

Variable n = 74 HbA1c < 7.0%
n = 38
HbA1c ≥ 7.0%
n = 36
p value
Age (years) 65.6 ± 6.8 66.0 ± 6.7 65.2 ± 7.1 0.62
Female gender, n (%) 26 (35.1) 10 (26.3) 16 (44.4) 0.10
Hypertension, n (%) 72 (97.3) 37 (97.4) 35 (97.2) 0.97
Hyperlipidemia, n (%) 50 (67.6) 24 (63.2) 26 (72.2) 0.41
Metabolic syndrome, n (%) 74 (100.0) 38 (100.0) 36 (100.0) 1.00
Obesity, n (%) 49 (66.2) 26 (68.4) 23 (63.9) 0.68
Waist circumference (cm) 106.5 ± 9.4 106.7 ± 9.1 106.2 ± 9.8 0.83
Body mass index, kg/m2 31.2 ± 3.6 31.1 ± 3.0 31.3 ± 4.1 0.81
Body fat (%) 34.1 ± 8.6 32.9 ± 7.4 35.4 ± 9.6 0.23
Visceral fat (%) 16.0 ± 4.7 16.4 ± 5.0 15.5 ± 4.2 0.53
Total body water (%) 47.6 (44.2; 49.3) 48.6 (44.2; 49.3) 47.2 (44.0; 49.1) 0.45
Muscle mass (kg) 55.2 ± 10.4 56.1 ± 8.6 54.0 ± 12.7 0.51
Medical history
 T2DM duration (years) 10 (6; 15) 9 (4; 10) 10 (7; 20) 0.02
 CAD, n (%) 74 (100.0) 38 (100.0) 36 (100.0) 1.00
 PAD, n (%) 26 (35.1) 10 (26.3) 16 (44.4) 0.10
 Previous MI, n (%) 28 (37.8) 17 (44.7) 11 (30.6) 0.21
 Previous PCI, n (%) 47 (65.5) 25 (65.8) 22 (61.1) 0.68
Treatment
 ASA, n (%) 74 (100.0) 38 (100.0) 36 (100.0) 1.00
 Clopidogrel, n (%) 33 (44.5) 16 (42.1) 17 (47.2) 0.66
 Beta blocker, n (%) 61 (82.4) 32 (84.2) 29 (80.6) 0.68
 ACE inhibitor or ARB, n (%) 67 (90.5) 33 (86.8) 34 (94.4) 0.26
 Nitrate long acting, n (%) 11 (14.9) 5 (13.2) 6 (16.7) 0.67
 Calcium antagonist, n (%) 32 (43.2) 15 (39.5) 17 (47.2) 0.50
 Statin, n (%) 68 (91.9) 34 (89.5) 34 (94.4) 0.43
 Fibrate, n (%) 1 (1.4) 0 1 (2.8) 0.30
 Diuretic, n (%) 22 (29.7) 9 (23.7) 13 (36.1) 0.24
 MRA, n (%) 9 (12.2) 4 (10.5) 5 (13.9) 0.66
 Metformin, n (%) 49 (66.2) 27 (71.1) 22 (61.1) 0.37
 Sulfonylurea, n (%) 31 (41.9) 19 (50.0) 12 (33.3) 0.15
 Acarbose, n (%) 1 (1.4) 0 1 (2.8) 0.30
 DPP-IV, n (%) 3 (4.1) 2 (5.3) 1 (2.8) 0.59
 Insulin, n (%) 32 (43.2) 9 (23.7) 23 (63.9) 0.0005
 PPI, n (%) 22 (29.7) 9 (23.7) 13 (36.1) 0.24
  1. Data are given as number (percentage) for categorical variables and mean (± standard deviation) or median (IQR) for continuous variables
  2. Italic values indicate significance of p value (p < 0.05)
  3. ACE angiotensin-converting enzyme, ARB angiotensin II receptor blocker, ASA acetylsalicylic acid, CAD coronary artery disease, MI myocardial infarction, MRA mineralocorticoid receptor antagonist, PAD peripheral artery disease, PCI percutaneous coronary intervention, PPI proton pump inhibitor, T2DM type 2 diabetes mellitus